Bausch + Lomb competitors

Patrick Miles is a Chairman & CEO at Aphatec Spine and is based in San Diego, California. She has experience at Smith & Nephew and has worked as Chairman at ALPHATEC HOLDINGS, INC.; Exec VP:Product Mktg & Dev at NUVASIVE INC; and Board Member at NUVASIVE INC. Patrick studied at MERCER UNIVERSITY between 1984 and 1988.

José E. Almeida is a Brazilian businessman. He has served as the chairman and CEO of Baxter International, Inc. since January 2016. He worked for Tyco Healthcare from 1995 to 2002. He was president of Medical Devices division from October 2006 to June 2011. He served as chairman of the board of directors of Covidien since March 2012 and as the president, chief executive officer and a director since July 2011. He became a director of EMC Corporation on Jan 12, 2015 and resigned on October 30, 2015, due to his election as chairman and CEO of Baxter. In 2015, he worked for The Carlyle Group as an Operating Executive in the Global Healthcare group.

Curt R. Hartman is the President and Chief Executive Officer of CONMED Corporation. He was appointed to the Board of Directors of CONMED on March 1, 2014, assumed the Interim CEO role on July 22, 2014, and became the full-time President and CEO on November 9, 2014. Prior to CONMED, he had a twenty-two-year career at Stryker Corporation (“Stryker”), a publicly-traded large-cap medical device company, from 1990 through February 2013. During his tenure with Stryker, he served as Interim Chief Executive Officer from February 2012 to October 2012 and as Vice President and Chief Financial Officer from April 2009 to October 2012. Mr. Hartman initially joined Stryker as a Manufacturing Engineer. He subsequently held roles of increasing responsibility to include Unit Supervisor, Production Unit Manager, Director of Information Technology, National Accounts Director and Vice President, General Manager, and Global President of the Instruments Division. Mr. Hartman has a Bachelor of Science degree in Aerospace Engineering from the University of Michigan and holds a Harvard AMP Program Certificate from Harvard Business School. He also has completed the Stryker Advanced Leadership Program at Harvard Business School. Mr. Hartman currently serves on the Board of Veran Medical Technologies, a venture-backed medical technology company.

An accomplished Board Chairman, Chief Executive Officer, and civic leader, with a career built on professional will and personal humility. Strengths: Moral Fortitude, General Management, Entrepreneurship, Business Strategy, Applied Technology, Deal Making. (Note: Please do not use LinkedIn email to request meetings or responses. I rarely check LinkedIn email and even less frequently respond. I ask respectfully, so we both use our time and efforts productively. Thank you.)

As CEO, Andres Lopez’s focus is to enhance the performance of the business to benefit customers, employees, investors and other key stakeholders. Lopez has established himself as a strong and successful leader, most recently serving as chief operating officer during 2015 and playing a key leading role on the recent acquisition of Vitro’s Food and Beverage business in Mexico, the U.S. and Bolivia. He has also served as president of O-I Americas, with a focus on strengthening O-I’s North America operations. Prior to that role, he served as president of O-I’s South America operations, where he led the region through significant organic and acquisition-based growth, adding new capabilities in Brazil and Argentina. Lopez has held various other leadership positions at O-I, including global vice president of manufacturing and engineering; vice president of manufacturing, North America; and country general manager for O-I Peru.

David J. Endicott is the CEO of Alcon, a member of its Board of Directors, and leads the Alcon Executive Committee. He joined Alcon in July of 2016 as Chief Operating Officer. Prior to Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. During his tenure there, he led Hospira’s medical device business through a turnaround, carve-out, and eventual sale. Critical to the turnaround, he advanced the company’s product pipeline, returned its products to market from quality disruptions and accelerated global growth. Before joining Hospira, David served as an officer and executive committee member of Allergan where he spent more than 25 years of his career in leadership roles across Europe, Asia, Latin America and the US. He accelerated Allergan’s international growth and successfully built new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and aesthetic medicine. He currently serves on the Board of Directors of AdvaMed, and has previously served on the Boards of Zeltiq (NASDAQ: ZLTQ), and Orexigen (NASDAQ: OREX). David holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School.

Philip 'Phil' Blake is an Head:US Region at Bayer Schering Pharma, President/CEO at Bayer, and Board Member at Nexia Biotechnologies. He has worked as Exec VP at Bayer, Senior VP at Bayer, and Head at Bayer HealthCare.